ArriVent BioPharma (AVBP) Total Current Liabilities (2023 - 2026)
ArriVent BioPharma (AVBP) reported Total Current Liabilities of $25.0 million for Q1 2026, up 92.97% on a YoY basis from $13.0 million in Q1 2025, and down 3.66% sequentially from $25.9 million in Q4 2025.
ArriVent BioPharma (AVBP) Total Current Liabilities (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Total Current Liabilities data on file, last reported at $25.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 92.97% year-over-year to $25.0 million; the trailing twelve-month figure through Mar 2026 stood at $25.0 million (up 92.97% YoY), and the FY2025 full-year result was $25.9 million, up 50.2% from the prior year.
- Total Current Liabilities eased to $25.0 million in Q1 2026, from $25.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $25.9 million in Q4 2025 to a low of $10.0 million in Q1 2024.
- A 4-year average of $17.1 million and a median of $16.2 million in 2024 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities rose 29.83% in 2025 and jumped 92.97% in 2026, its largest moves.
- Tracing AVBP's Total Current Liabilities over 4 years: stood at $11.6 million in 2023, then jumped by 48.61% to $17.3 million in 2024, then soared by 50.2% to $25.9 million in 2025, then declined by 3.66% to $25.0 million in 2026.
- Business Quant data shows AVBP's Total Current Liabilities at $25.0 million in Q1 2026, $25.9 million in Q4 2025, and $21.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | 25.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.00 Mn |
| Dec 31, 2025 | 25.95 Mn |
| Sep 30, 2025 | 21.56 Mn |
| Jun 30, 2025 | 19.64 Mn |
| Mar 31, 2025 | 12.95 Mn |
| Dec 31, 2024 | 17.27 Mn |
| Sep 30, 2024 | 15.16 Mn |
| Jun 30, 2024 | 12.10 Mn |
| Mar 31, 2024 | 9.98 Mn |
| Dec 31, 2023 | 11.62 Mn |